Our look is new. Our purpose is the same. Learn more about our brand evolution.
[…] a locally-acting “Myostatin+” muscle agent, for the treatment of patients with facioscapulohumeral muscular dystrophy ( FSHD). “This is an important milestone in the development of ACE-083—our lead program within our […]
[…] that I had muscular dystrophy. I strongly urge anyone who has a family history of FSHD to get genetically tested because although there is no cure today, this doesn’t meant […]
We need YOU – to write to your senators by Anna Gilmore, FSHD Society Last year was an exciting one for our community as we launched our first FSHD Day […]
This webinar discusses anesthetic considerations for patients with FSHD, emphasizing that each anesthetic plan is tailored to the individual patient and procedure. The speaker is Bruna Castro de Oliveira, a […]
The FSHD Society is leading the global charge to find treatments and a cure for facioscapulohumeral muscular dystrophy (FSHD) while empowering individuals and families affected by the disease. As the […]
